AI-generated summary
This review article examines recent preclinical and clinical data on brain photobiomodulation therapy for neurological and psychological conditions. The authors describe proposed mechanisms, including red light stimulating mitochondrial ATP synthesis and calcium release, and mention potential use in depression, Parkinson's disease and dementia. They note that transcranial light delivery faces attenuation limits, which led to intranasal and intracranial approaches.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract does not report the number of studies or participants reviewed, and it does not state the strength of the evidence for effectiveness.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Adenosine triphosphate, Depression, Dementia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.